As of 2025-04-22, the Relative Valuation of Tarsus Pharmaceuticals, Inc. (TARS) is (37.80) USD. This relative valuation is based on P/E multiples. With the latest stock price at 48.51 USD, the upside of Tarsus Pharmaceuticals, Inc. based on Relative Valuation is -177.9%.
The range of the Relative Valuation is (33.52) - (45.24) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 12.1x - 16.3x | 14.0x |
| Forward P/E multiples | 10.4x - 16.5x | 13.2x |
| Fair Price | (33.52) - (45.24) | (37.80) |
| Upside | -169.1% - -193.3% | -177.9% |
| Date | P/E |
| 2025-04-22 | -17.65 |
| 2025-04-21 | -17.46 |
| 2025-04-17 | -17.72 |
| 2025-04-16 | -17.77 |
| 2025-04-15 | -17.67 |
| 2025-04-14 | -17.53 |
| 2025-04-11 | -16.71 |
| 2025-04-10 | -15.88 |
| 2025-04-09 | -16.51 |
| 2025-04-08 | -16.06 |
| 2025-04-07 | -17.09 |
| 2025-04-04 | -16.92 |
| 2025-04-03 | -17.83 |
| 2025-04-02 | -18.53 |
| 2025-04-01 | -17.60 |
| 2025-03-31 | -18.48 |
| 2025-03-28 | -18.62 |
| 2025-03-27 | -18.23 |
| 2025-03-26 | -18.36 |
| 2025-03-25 | -18.47 |
| 2025-03-24 | -18.84 |
| 2025-03-21 | -17.98 |
| 2025-03-20 | -17.96 |
| 2025-03-19 | -17.83 |
| 2025-03-18 | -16.61 |
| 2025-03-17 | -17.09 |
| 2025-03-14 | -17.30 |
| 2025-03-13 | -16.72 |
| 2025-03-12 | -16.95 |
| 2025-03-11 | -16.97 |
| 2025-03-10 | -16.04 |
| 2025-03-07 | -16.72 |
| 2025-03-06 | -15.68 |
| 2025-03-05 | -16.03 |
| 2025-03-04 | -16.01 |
| 2025-03-03 | -15.37 |
| 2025-02-28 | -16.01 |
| 2025-02-27 | -15.67 |
| 2025-02-26 | -15.31 |
| 2025-02-25 | -14.86 |
| 2025-02-24 | -16.39 |
| 2025-02-21 | -17.21 |
| 2025-02-20 | -17.53 |
| 2025-02-19 | -17.83 |
| 2025-02-18 | -18.30 |
| 2025-02-14 | -18.07 |
| 2025-02-13 | -18.79 |
| 2025-02-12 | -18.83 |
| 2025-02-11 | -18.43 |
| 2025-02-10 | -18.62 |